Mark Ragosa Sells 17,845 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 17,845 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the sale, the chief financial officer directly owned 12,086 shares in the company, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Thursday, January 8th, Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.89, for a total value of $502,680.00.
• On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.49, for a total transaction of $1,777,473.09.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ:KNSA opened at $44.71 on Friday. The company has a 50 day moving average price of $42.14 and a 200-day moving average price of $38.72. Kiniksa Pharmaceuticals International, plc has a 1-year low of $18.25 and a 1-year high of $45.50. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of 99.36 and a beta of 0.06.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC grew its position in shares of Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after purchasing an additional 250 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. Mariner LLC grew its holdings in Kiniksa Pharmaceuticals International by 5.8% in the 3rd quarter. Mariner LLC now owns 13,253 shares of the company’s stock valued at $515,000 after buying an additional 732 shares in the last quarter. CWM LLC grew its holdings in Kiniksa Pharmaceuticals International by 3.9% in the 4th quarter. CWM LLC now owns 20,605 shares of the company’s stock valued at $850,000 after buying an additional 764 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock worth $701,000 after acquiring an additional 771 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Analyst support remains: several sell-side firms have recent buy/outperform ratings and raised targets (Citigroup, Wedbush, Goldman Sachs among them), keeping longer-term sentiment constructive and implying upside vs. current price. MarketBeat Coverage
• Positive Sentiment: Large institutional holders continue to own meaningful stakes (Rubric, Vanguard, Arrowstreet, Acadian, Qube), which can support share demand and reduce volatility from retail flows. Institutional Ownership Details
• Neutral Sentiment: Short-interest reporting appears to be a data glitch (entries show “0 shares” and NaN increases); there’s no clear evidence of a new short-squeeze or large new short positions impacting near-term flows. (Likely reporting error.)
• Neutral Sentiment: Technical/context: KNSA sits near its 52-week high and above its 50- and 200-day moving averages — bullish technically but also means some traders may take gains at these levels.
• Negative Sentiment: Significant insider selling: CFO Mark Ragosa sold 17,845 shares at an average $43.28 (≈$772k) and recently reduced his stake materially (~59.6% reduction). Large officer sales often trigger short-term selling pressure or investor concern about insider conviction. Ragosa SEC Form 4
• Negative Sentiment: Additional insider sells: Director Barry D. Quart sold ~2,690 shares on Feb 12 (and 110 shares Feb 10) at ~$45, trimming his holdings. Multiple insiders selling within days can amplify negative investor reaction. Quart SEC Form 4

Analysts Set New Price Targets

Several brokerages recently weighed in on KNSA. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.